Combined modality radioimmunotherapy with taxol and 90Y-Lym-1 for Raji lymphoma xenografts

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 5, 1998, Pages 351-361

  O'Donnell, Robert T ^a,b   DeNardo, Sally J ^a   Miers, Laird A ^a   Kukis, David L ^a   Mirick, Gary R ^a   Kroger, Linda A ^a   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Radiodiagnosis and Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; PACLITAXEL; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BONE MARROW TOXICITY; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER TRANSPLANTATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

EID: 0032407933     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.351     Document Type: Article

References (4)

1. Armitage JO.Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-1030.
2. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52:5432s-5440s.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
4. 67Cu-2IT-BAT-Lym-l and opportunities for improvement. In:Cancer therapy with radiolabeled antibodies Goldenberg DM(ed) CRC Press, Boca Raton, Florida, 1995; 217.